Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.
A vaccine comprised of recombinant cytomegalovirus (CMV) envelope glycoprotein B (gB) with MF59 adjuvant developed in the 1990s recently was recently found to have efficacy for prevention of CMV infection in a phase 2 clinical trial in young mothers. This review briefly considers the rationale for gB as a vaccine antigen, the history of this CMV gB vaccine and the data supporting vaccine efficacy.
Pass
Robert F
RF
Department of Pediatrics, University of Alabama at Birmingham, USA. rpass@peds.uab.edu
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D017322:Clinical Trials, Phase II as Topic; D003586:Cytomegalovirus Infections / Q000151:congenital / Q000517:prevention & control*; D022482:Cytomegalovirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D011136:Polysorbates / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D013185:Squalene / Q000008:administration & dosage*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014759:Viral Envelope Proteins / Q000008:administration & dosage / Q000276:immunology*
D000276:Adjuvants, Immunologic; D022482:Cytomegalovirus Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; C040495:glycoprotein B, Simplexvirus; D013185:Squalene